Cargando…

DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA

DIPG is an aggressive paediatric brainstem tumour, with a median survival of less than 1 year. Polyamines are intracellular polycations that control important aspects of cell growth and are often upregulated in cancer. Difluoromethylornithine (DFMO) is an FDA-approved inhibitor of the enzyme ornithi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Aaminah, Gamble, Laura, Upton, Dannielle, Yu, Denise, Ehteda, Anahid, Pandher, Ruby, Mayoh, Chelsea, Burns, Mark, Norris, Murray, Haber, Michelle, Tsoli, Maria, Ziegler, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715550/ http://dx.doi.org/10.1093/neuonc/noaa222.065

Ejemplares similares

DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Khan, Aaminah, et al.
Publicado: (2020)

DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION
por: Ehteda, Anahid, et al.
Publicado: (2020)

DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)
por: Upton, Dannielle, et al.
Publicado: (2020)

DIPG-21. DIPG cells alter the permeability of the blood-brain barrier in the brainstem leading to treatment failure.
por: Ung, Caitlin, et al.
Publicado: (2022)

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)
por: Holliday, Holly, et al.
Publicado: (2022)

DIPG-14. TARGETING POLO-LIKE KINASE 1 IN COMBINATION WITH KEY ONCOGENIC DRIVERS IN DIPG: FROM SINGLE AGENT TO COMBINATION STRATEGIES
por: Franshaw, Laura, et al.
Publicado: (2020)

DIPG-20. Copper chelation therapy targets S-adenosylmethionine (SAM) metabolism and epigenetic regulators in diffuse intrinsic pontine glioma (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2022)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-83. USING COPPER CHELATING AGENTS TO TARGET RECEPTOR TYROSINE KINASE SIGNALLING IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Michniewicz, Filip, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-29. PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE (PI3K) INHIBITION DRIVES PROTEIN KINASE C ACTIVATION (PKC) IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Duchatel, Ryan J, et al.
Publicado: (2020)

DIPG-49. BRAINSTEM AND PONTINE VOLUMETRIC ANALYSIS AS A SURROGATE MEASURE OF LOCAL DISEASE CONTROL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Bander, Evan D, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)

DIPG-01. REIRRADIATION PRACTICES FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Cacciotti, Chantel, et al.
Publicado: (2020)

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

DIPG-84. COMPLEMENTARY AND ALTERNATIVE MEDICINE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma, et al.
Publicado: (2020)

DIPG-10. OPTIMAL HDAC INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Vitanza, Nicholas, et al.
Publicado: (2020)

DIPG-13. TARGETING HYPOXIA AND MITOCHONDRIA WITH REPURPOSED METABOLIC DRUGS AS AN APPROACH TO RADIOSENSITIZATION FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
por: Shen, Han, et al.
Publicado: (2020)

DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG
por: Sanguino, Yolanda Colino, et al.
Publicado: (2022)

DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY
por: Cooney, Tabitha, et al.
Publicado: (2020)

DIPG-18. Evaluating drug distribution in children with diffuse intrinsic pontine glioma (DIPG) treated with convection-enhanced drug delivery
por: Szychot, Elwira, et al.
Publicado: (2022)

DIPG-77. TREATMENT EXTENT AND THE EFFECT ON SURVIVAL IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Baugh, Joshua, et al.
Publicado: (2020)

DIPG-18. IDENTIFICATION OF TARGETABLE PATHWAY DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Parackal, Sarah, et al.
Publicado: (2020)

DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Katagi, Hiroaki, et al.
Publicado: (2020)

DIPG-33. CHARACTERIZING THE NEURO-VASCULAR UNIT IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma E, et al.
Publicado: (2020)

DIPG-02. Role of a Bevacizumab-based regime in the treatment of children with diffuse intrinsic pontine glioma (DIPG): a systematic review
por: Evans, Mia, et al.
Publicado: (2022)

DIPG-22. DISSECTING THE ONCOGENIC ROLE OF FOXR2 IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Tsai, Jessica W, et al.
Publicado: (2020)

DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM
por: Khuong-Quang, Dong-Anh, et al.
Publicado: (2020)

DIPG-62. Reducing the levels of genomic 5-hydroxymethylcytosine by inhibiting the TET pathway induces apoptosis and decreases proliferation in Diffuse Intrinsic Pontine Glioma (DIPG)
por: Parthasarathy, Akhila, et al.
Publicado: (2022)

DIPG-14. Neogenin Knockout Stops the Invasion and Dissemination of Diffuse Intrinsic Pontine Gliomasin vivo.
por: Sesen, Julie, et al.
Publicado: (2022)

DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
por: Grill, Jacques, et al.
Publicado: (2020)

DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Borsuk, Robyn, et al.
Publicado: (2020)

DIPG-25. Patterns of cerebrospinal fluid diversion and survival in children with diffuse intrinsic pontine glioma: a report from the International Diffuse Intrinsic Pontine Glioma Registry
por: Cooney, Tabitha, et al.
Publicado: (2022)

DIPG-72. LONG-TERM SURVIVAL OF A CLASSIC DIFFUSE INTRINSIC PONTINE GLIOMA TREATED WITH NIMOTUZUMAB
por: Epelman, Sidnei, et al.
Publicado: (2020)

DIPG-21. INDUCTION OF MITOTIC ABNORMALITIES AND BMI-1 MODULATION TO TREAT DIFFUSE INTRINSIC PONTINE GLIOMA
por: Kumar, Shiva Senthil, et al.
Publicado: (2020)

DIPG-02. USEFULNESS OF BEVACIZUMAB IN MAINTAINING QUALITY OF LIFE AT THE TIME OF DIFFUSE INTRINSIC PONTINE GLIOMA RELAPSE
por: Gomi, Akira, et al.
Publicado: (2020)

DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Adorno, Jennifer Ocasio, et al.
Publicado: (2020)

DIPG-36. The brain-gut-microbiota axis to predict outcome in pediatric diffuse intrinsic pontine glioma
por: De Cecco, Loris, et al.
Publicado: (2022)

DIPG-54. p53 pathway reactivation as a therapeutic strategy in diffuse intrinsic pontine glioma
por: Lupien, Leslie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_th09e188ruaf6al1a92ej5hl29